<DOC>
	<DOCNO>NCT01854437</DOCNO>
	<brief_summary>Hyperphosphatemia common problem hemodialysis ( HD ) patient . Different chelators control Hyperphosphatemia use . The aim study assess effect magnesium oxide ( Mg Oxide ) control serum phosphorus ( P ) level evaluation side effect hemodialysis patient .</brief_summary>
	<brief_title>The Effect Magnesium Oxide Plasma Phosphate Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>hemodialysis duration &gt; 3 month serum P level &gt; 5.5 mg/dl serum Ca &gt; 8 mg/dl . Mg level &gt; 3 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>mg oxide</keyword>
	<keyword>hyperphosphatemia</keyword>
	<keyword>plasma phosphor level</keyword>
</DOC>